Share price · SYRE
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when SYRE's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 18 Nov 2026+8.2%
Nothing announced by SYRE that day or the session before.
- 6 Oct 2026-13.6%
- 26 Aug 2026-12.8%
- 4 Aug 2026+10.5%
- 24 Jun 2026-11.1%
Nothing announced by SYRE that day or the session before.
- 22 Jun 2026+13.6%
Nothing announced by SYRE that day or the session before.
- 13 Apr 2026+23.4%
- 16 Mar 2026+10.5%
- 20 Feb 2026+14.3%
- 12 Jan 2026+7.2%
Share of unusual movement by asset
For each asset, the share of SYRE's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(4 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | α4β7 integrinMonoclonal antibody | Inflammatory Bowel Disease Ulcerative Colitis | |
| Phase 2 | TL1AMonoclonal antibody | Inflammatory Bowel Disease Ulcerative Colitis | |
| Phase 2 | IL-23 p19Monoclonal antibody | Inflammatory Bowel Disease Ulcerative Colitis | |
| Phase 2 | TL1AMonoclonal antibody | Hidradenitis Suppurativa |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (2)
June 2027 (1)
Regulatory and conference events
(5)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $89M | $83M+ $989M short-term inv. | $96M-$77M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $66M | $162M+ $983M short-term inv. | $36M-$70M operating cash flow | report ↗ |
| 2026-Q1 | — | $60M | $742M | $57M | report ↗ |
| 2025-Q3 | — | $45M | $65M+ $421M short-term inv. | $11M-$37M operating cash flow | report ↗ |
| 2025-Q2 | — | $40M | $82M+ $445M short-term inv. | $37M-$47M operating cash flow | report ↗ |
| 2025-Q1 | — | $42M | $48M+ $516M short-term inv. | $45M-$41M operating cash flow | report ↗ |
| 2024-Q3 | $0 | $45M | $72M+ $343M short-term inv. | $69M-$29M operating cash flow | report ↗ |
| 2024-Q2 | $0 | $33M | $45M+ $381M short-term inv. | $39M-$62M operating cash flow | report ↗ |
| 2024-Q1 | $0 | $35M | $228M+ $257M short-term inv. | $44M-$29M operating cash flow | report ↗ |
| 2023-Q3 | $0 | $25M | $92M+ $113M short-term inv. | $40M-$35M operating cash flow | report ↗ |
| 2023-Q2 | $0.7M | $17M | $237M+ $0 short-term inv. | $217M-$17M operating cash flow | report ↗ |
| 2023-Q1 | $0.2M | $14M | $37M+ $3.2M short-term inv. | $18M-$18M operating cash flow | report ↗ |
| 2022-Q3 | $0.2M | $12M | $41M+ $35M short-term inv. | $18M-$15M operating cash flow | report ↗ |
| 2022-Q2 | $0.6M | $15M | —+ $51M short-term inv. | $22M-$21M operating cash flow | report ↗ |
| 2022-Q1 | $1.4M | — | —+ $52M short-term inv. | $24M-$26M operating cash flow | report ↗ |
| 2021-Q3 | $1.4M | — | —+ $88M short-term inv. | $20M-$17M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0 | $172M | $86M+ $671M short-term inv. | $39M-$169M operating cash flow | report ↗ |
For fiscal year 2025, Spyre Therapeutics reported revenue of $0M (prior year $0M), R&D spend of $171.65M, up 5.4% YoY, cash and equivalents of $85.72M, a net loss of $155.2M, and a quarterly net burn of $155.2M.
Spyre is a clinical-stage biotechnology company developing long-acting antibody monotherapies and combinations for inflammatory bowel disease and rheumatic diseases. It initiated the SKYLINE Phase 2 platform trial in May 2025 evaluating SPY001, SPY002, SPY003 and pairwise combinations in moderately to severely active ulcerative colitis, with Part A induction data expected to begin reading out in Q2 2026, and is running the SKYWAY Phase 2 basket trial of SPY072 in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $0 | $163M | $89M+ $514M short-term inv. | $52M-$157M operating cash flow | report ↗ |
| 2023-FY | $0.9M | $90M | $189M+ $150M short-term inv. | $85M-$100M operating cash flow | report ↗ |
| 2022-FY | $2.3M | $59M | $36M+ $21M short-term inv. | $21M-$80M operating cash flow | report ↗ |
| 2021-FY | $19M | $57M | $17M+ $78M short-term inv. | $16M-$54M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 94 sales ($441.9M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-01 | Turtle Cameron · director, Chief Executive Officer | Open-market sale | 600 | $89.14 | $53K | Form 4 |
| 2026-10-01 | King-Jones Heidy · See Remarks | Option exercise | 28,933 | $14.50 | $420K | Form 4 |
| 2026-10-01 | Turtle Cameron · director, Chief Executive Officer | Open-market sale | 2,683 | $90.10 | $242K | Form 4 |
| 2026-10-01 | King-Jones Heidy · See Remarks | Open-market sale | 400 | $89.24 | $36K | Form 4 |
| 2026-10-01 | Burrows Scott L · Chief Financial Officer | Option exercise | 7,500 | $14.50 | $109K | Form 4 |
| 2026-10-01 | Turtle Cameron · director, Chief Executive Officer | Open-market sale | 2,638 | $91.49 | $241K | Form 4 |
| 2026-10-01 | King-Jones Heidy · See Remarks | Open-market sale | 16,605 | $90.35 | $1.5M | Form 4 |
| 2026-10-01 | Burrows Scott L · Chief Financial Officer | Open-market sale | 600 | $89.07 | $53K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 197 reporting institutions held 82.8M shares ($4.1B, 87.2% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | FMR LLC | 11,781,024 | $594.2M |
| 2 | BlackRock, Inc. | 5,521,221 | $278.5M |
| 3 | RTW INVESTMENTS, LP | 4,171,996 | $210.4M |
| 4 | Fairmount Funds Management LLC | 4,018,101 | $202.7M |
| 5 | PERCEPTIVE ADVISORS LLC | 3,783,225 | $190.8M |
| 6 | Venrock Adviser, LLC | 3,685,448 | $185.9M |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 3,057,401 | $154.2M |
| 8 | Driehaus Capital Management LLC | 2,790,785 | $140.8M |
| 9 | STATE STREET CORP | 2,607,031 | $131.5M |
| 10 | Paradigm Biocapital Advisors LP | 1,957,266 | $98.7M |
| 11 | Commodore Capital LP | 1,912,380 | $96.5M |
| 12 | TCG Crossover Management, LLC | 1,900,582 | $95.9M |
| 13 | TANG CAPITAL MANAGEMENT LLC | 1,892,200 | $95.4M |
| 14 | WELLINGTON MANAGEMENT GROUP LLP | 1,824,811 | $92.0M |
| 15 | Capital International Investors | 1,746,129 | $88.1M |